The closing price of Arbutus Biopharma Corp (NASDAQ: ABUS) was $2.67 for the day, down -1.48% from the previous closing price of $2.71. In other words, the price has decreased by -$0.0400 from its previous closing price. On the day, 620879 shares were traded.
Ratios:
Our analysis of ABUS’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 6.34 and its Current Ratio is at 5.87. In the meantime, Its Debt-to-Equity ratio is 0.08 whereas as Long-Term Debt/Eq ratio is at 0.08.
On February 25, 2021, Jefferies started tracking the stock assigning a Hold rating and target price of $5.
On December 17, 2020, H.C. Wainwright started tracking the stock assigning a Buy rating and target price of $10.H.C. Wainwright initiated its Buy rating on December 17, 2020, with a $10 target price.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Feb 02 when McElhaugh Michael J. sold 10,164 shares for $2.31 per share. The transaction valued at 23,504 led to the insider holds 1,504,793 shares of the business.
Sofia Michael J. sold 9,982 shares of ABUS for $23,083 on Feb 02. The Chief Scientific Officer now owns 1,485,121 shares after completing the transaction at $2.31 per share. On Feb 02, another insider, HASTINGS DAVID C, who serves as the Chief Financial Officer of the company, sold 9,593 shares for $2.31 each. As a result, the insider received 22,184 and left with 181,907 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ABUS now has a Market Capitalization of 455.33M and an Enterprise Value of 323.06M. For the stock, the TTM Price-to-Sale (P/S) ratio is 24.68 while its Price-to-Book (P/B) ratio in mrq is 4.28. Its current Enterprise Value per Revenue stands at 14.53 whereas that against EBITDA is -4.40.
Stock Price History:
Over the past 52 weeks, ABUS has reached a high of $3.14, while it has fallen to a 52-week low of $1.69. The 50-Day Moving Average of the stock is 2.5554, while the 200-Day Moving Average is calculated to be 2.2155.
Shares Statistics:
ABUS traded an average of 984.75K shares per day over the past three months and 857.21k shares per day over the past ten days. A total of 169.90M shares are outstanding, with a floating share count of 125.20M. Insiders hold about 25.34% of the company’s shares, while institutions hold 46.92% stake in the company. Shares short for ABUS as of Feb 15, 2024 were 3.69M with a Short Ratio of 3.75, compared to 6.43M on Jan 12, 2024. Therefore, it implies a Short% of Shares Outstanding of 2.17% and a Short% of Float of 2.88%.
Earnings Estimates
The firm’s stock currently is rated by 4 analysts. On average, analysts expect EPS of -$0.11 for the current quarter, with a high estimate of -$0.1 and a low estimate of -$0.13, while EPS last year was -$0.1. The consensus estimate for the next quarter is -$0.11, with high estimates of -$0.09 and low estimates of -$0.14.
Analysts are recommending an EPS of between -$0.38 and -$0.6 for the fiscal current year, implying an average EPS of -$0.45. EPS for the following year is -$0.53, with 3 analysts recommending between -$0.43 and -$0.68.
Revenue Estimates
It is expected that $90B in revenue will be generated in the current quarter, according to 3 analysts. It ranges from a high estimate of $2.21M to a low estimate of $2.1M. As of the current estimate, Arbutus Biopharma Corp’s year-ago sales were $6.69M, an estimated decrease of -68.00% from the year-ago figure. For the next quarter, 3 analysts are estimating revenue of $2.16M, a decrease of -53.60% over than the figure of -$68.00% in the same quarter last year. There is a high estimate of $2.28M for the next quarter, whereas the lowest estimate is $2.1M.
A total of 4 analysts have provided revenue estimates for ABUS’s current fiscal year. The highest revenue estimate was $9.27M, while the lowest revenue estimate was $4.6M, resulting in an average revenue estimate of $7.77M. In the same quarter a year ago, actual revenue was $18.14M, down -57.20% from the average estimate. Based on 3 analysts’ estimates, the company’s revenue will be $10.03M in the next fiscal year. The high estimate is $10.88M and the low estimate is $8.6M. The average revenue growth estimate for next year is up 29.10% from the average revenue estimate for this year.
